Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.
Identifieur interne : 000121 ( PubMed/Curation ); précédent : 000120; suivant : 000122Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.
Auteurs : Kwamena William Coleman Sagoe [Ghana] ; Afrakoma Adjoa Agyei ; Francesca Ziga ; Margaret Lartey ; Theophilus K. Adiku ; Makafui Seshi ; Max Q. Arens ; Julius Abraham Addo MingleSource :
- Journal of medical virology [ 1096-9071 ] ; 2012.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Agents antiVIH (administration et posologie), Anticorps de l'hépatite C (sang), Antigènes de surface du virus de l'hépatite B (sang), Charge virale, Co-infection (épidémiologie), Comorbidité, Femelle, Ghana, Humains, Hépatite B (), Hépatite B (épidémiologie), Hépatite C (), Hépatite C (épidémiologie), Immunoglobuline M (sang), Infections à VIH (), Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Mâle, Numération des lymphocytes CD4, Thérapie antirétrovirale hautement active (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification).
- MESH :
- administration et posologie : Agents antiVIH.
- isolement et purification : VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- sang : Anticorps de l'hépatite C, Antigènes de surface du virus de l'hépatite B, Immunoglobuline M.
- traitement médicamenteux : Infections à VIH.
- virologie : Infections à VIH.
- épidémiologie : Co-infection, Hépatite B, Hépatite C.
- Adulte, Adulte d'âge moyen, Charge virale, Comorbidité, Femelle, Ghana, Humains, Hépatite B, Hépatite C, Infections à VIH, Mâle, Numération des lymphocytes CD4, Thérapie antirétrovirale hautement active.
- Wicri :
- geographic : Ghana.
English descriptors
- KwdEn :
- Adult, Anti-HIV Agents (administration & dosage), Antiretroviral Therapy, Highly Active (methods), CD4 Lymphocyte Count, Coinfection (epidemiology), Comorbidity, Female, Ghana, HIV Infections (complications), HIV Infections (drug therapy), HIV Infections (virology), HIV-1 (isolation & purification), Hepatitis B (complications), Hepatitis B (epidemiology), Hepatitis B Surface Antigens (blood), Hepatitis C (complications), Hepatitis C (epidemiology), Hepatitis C Antibodies (blood), Humans, Immunoglobulin M (blood), Male, Middle Aged, Viral Load.
- MESH :
- chemical , administration & dosage : Anti-HIV Agents.
- chemical , blood : Hepatitis B Surface Antigens, Hepatitis C Antibodies, Immunoglobulin M.
- geographic : Ghana.
- complications : HIV Infections, Hepatitis B, Hepatitis C.
- drug therapy : HIV Infections.
- epidemiology : Coinfection, Hepatitis B, Hepatitis C.
- isolation & purification : HIV-1.
- methods : Antiretroviral Therapy, Highly Active.
- virology : HIV Infections.
- Adult, CD4 Lymphocyte Count, Comorbidity, Female, Humans, Male, Middle Aged, Viral Load.
Abstract
Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co-infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was screened for HBV and HCV serologic markers; HBsAg positive patients were tested for HBeAg, anti-HBe, and anti-HBc IgM. The viral load of HIV-1 in the plasma was determined in 81 patients. Eighteen of the 138 patients (13%) and 5 (3.6%) had HBsAg and anti-HCV, respectively. None of the patients had anti-HBc IgM, but 10 (55.6%) and 8 (44.4%) of the 18 patients who were HBsAg positive had HBeAg and anti-HBe, respectively. In patients with measurement of CD4(+) undertaken within 1 month (n = 83), CD4(+) count was significantly lower in patients with HBeAg (median [IQR], 81 [22-144]) as compared to those with anti-HBe (median [IQR], 210 [197-222]) (P = 0.002, CI: -96.46 to 51.21). However, those with HIV mono-infection had similar CD4(+) counts (median [IQR], 57 [14-159]) compared to those with HBeAg (P = 1.0, CI: -71.75 to 73.66). Similar results were obtained if CD4(+) count was measured within 2 months prior to initiation of HAART (n = 119). Generally, HBV and anti-HCV did not affect CD4(+) and viral loads of HIV-1 in plasma but patients with HIV and HBV co-infection who had HBeAg had more severe immune suppression as compared to those with anti-HBe. This may have implication for initiating HAART in HBV endemic areas.
DOI: 10.1002/jmv.22262
PubMed: 22095533
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000121
Links to Exploration step
pubmed:22095533Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.</title><author><name sortKey="Sagoe, Kwamena William Coleman" sort="Sagoe, Kwamena William Coleman" uniqKey="Sagoe K" first="Kwamena William Coleman" last="Sagoe">Kwamena William Coleman Sagoe</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School, Accra, Ghana. kwcsagoe@chs.edu.gh</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School, Accra</wicri:regionArea></affiliation></author><author><name sortKey="Agyei, Afrakoma Adjoa" sort="Agyei, Afrakoma Adjoa" uniqKey="Agyei A" first="Afrakoma Adjoa" last="Agyei">Afrakoma Adjoa Agyei</name></author><author><name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name></author><author><name sortKey="Adiku, Theophilus K" sort="Adiku, Theophilus K" uniqKey="Adiku T" first="Theophilus K" last="Adiku">Theophilus K. Adiku</name></author><author><name sortKey="Seshi, Makafui" sort="Seshi, Makafui" uniqKey="Seshi M" first="Makafui" last="Seshi">Makafui Seshi</name></author><author><name sortKey="Arens, Max Q" sort="Arens, Max Q" uniqKey="Arens M" first="Max Q" last="Arens">Max Q. Arens</name></author><author><name sortKey="Mingle, Julius Abraham Addo" sort="Mingle, Julius Abraham Addo" uniqKey="Mingle J" first="Julius Abraham Addo" last="Mingle">Julius Abraham Addo Mingle</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22095533</idno><idno type="pmid">22095533</idno><idno type="doi">10.1002/jmv.22262</idno><idno type="wicri:Area/PubMed/Corpus">000121</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000121</idno><idno type="wicri:Area/PubMed/Curation">000121</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000121</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.</title><author><name sortKey="Sagoe, Kwamena William Coleman" sort="Sagoe, Kwamena William Coleman" uniqKey="Sagoe K" first="Kwamena William Coleman" last="Sagoe">Kwamena William Coleman Sagoe</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School, Accra, Ghana. kwcsagoe@chs.edu.gh</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School, Accra</wicri:regionArea></affiliation></author><author><name sortKey="Agyei, Afrakoma Adjoa" sort="Agyei, Afrakoma Adjoa" uniqKey="Agyei A" first="Afrakoma Adjoa" last="Agyei">Afrakoma Adjoa Agyei</name></author><author><name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name></author><author><name sortKey="Adiku, Theophilus K" sort="Adiku, Theophilus K" uniqKey="Adiku T" first="Theophilus K" last="Adiku">Theophilus K. Adiku</name></author><author><name sortKey="Seshi, Makafui" sort="Seshi, Makafui" uniqKey="Seshi M" first="Makafui" last="Seshi">Makafui Seshi</name></author><author><name sortKey="Arens, Max Q" sort="Arens, Max Q" uniqKey="Arens M" first="Max Q" last="Arens">Max Q. Arens</name></author><author><name sortKey="Mingle, Julius Abraham Addo" sort="Mingle, Julius Abraham Addo" uniqKey="Mingle J" first="Julius Abraham Addo" last="Mingle">Julius Abraham Addo Mingle</name></author></analytic><series><title level="j">Journal of medical virology</title><idno type="eISSN">1096-9071</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-HIV Agents (administration & dosage)</term><term>Antiretroviral Therapy, Highly Active (methods)</term><term>CD4 Lymphocyte Count</term><term>Coinfection (epidemiology)</term><term>Comorbidity</term><term>Female</term><term>Ghana</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (virology)</term><term>HIV-1 (isolation & purification)</term><term>Hepatitis B (complications)</term><term>Hepatitis B (epidemiology)</term><term>Hepatitis B Surface Antigens (blood)</term><term>Hepatitis C (complications)</term><term>Hepatitis C (epidemiology)</term><term>Hepatitis C Antibodies (blood)</term><term>Humans</term><term>Immunoglobulin M (blood)</term><term>Male</term><term>Middle Aged</term><term>Viral Load</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Agents antiVIH (administration et posologie)</term><term>Anticorps de l'hépatite C (sang)</term><term>Antigènes de surface du virus de l'hépatite B (sang)</term><term>Charge virale</term><term>Co-infection (épidémiologie)</term><term>Comorbidité</term><term>Femelle</term><term>Ghana</term><term>Humains</term><term>Hépatite B ()</term><term>Hépatite B (épidémiologie)</term><term>Hépatite C ()</term><term>Hépatite C (épidémiologie)</term><term>Immunoglobuline M (sang)</term><term>Infections à VIH ()</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (virologie)</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>Thérapie antirétrovirale hautement active ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Hepatitis B Surface Antigens</term><term>Hepatitis C Antibodies</term><term>Immunoglobulin M</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents antiVIH</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term><term>Hepatitis B</term><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coinfection</term><term>Hepatitis B</term><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Antiretroviral Therapy, Highly Active</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps de l'hépatite C</term><term>Antigènes de surface du virus de l'hépatite B</term><term>Immunoglobuline M</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Co-infection</term><term>Hépatite B</term><term>Hépatite C</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>CD4 Lymphocyte Count</term><term>Comorbidity</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Viral Load</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Charge virale</term><term>Comorbidité</term><term>Femelle</term><term>Ghana</term><term>Humains</term><term>Hépatite B</term><term>Hépatite C</term><term>Infections à VIH</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>Thérapie antirétrovirale hautement active</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co-infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was screened for HBV and HCV serologic markers; HBsAg positive patients were tested for HBeAg, anti-HBe, and anti-HBc IgM. The viral load of HIV-1 in the plasma was determined in 81 patients. Eighteen of the 138 patients (13%) and 5 (3.6%) had HBsAg and anti-HCV, respectively. None of the patients had anti-HBc IgM, but 10 (55.6%) and 8 (44.4%) of the 18 patients who were HBsAg positive had HBeAg and anti-HBe, respectively. In patients with measurement of CD4(+) undertaken within 1 month (n = 83), CD4(+) count was significantly lower in patients with HBeAg (median [IQR], 81 [22-144]) as compared to those with anti-HBe (median [IQR], 210 [197-222]) (P = 0.002, CI: -96.46 to 51.21). However, those with HIV mono-infection had similar CD4(+) counts (median [IQR], 57 [14-159]) compared to those with HBeAg (P = 1.0, CI: -71.75 to 73.66). Similar results were obtained if CD4(+) count was measured within 2 months prior to initiation of HAART (n = 119). Generally, HBV and anti-HCV did not affect CD4(+) and viral loads of HIV-1 in plasma but patients with HIV and HBV co-infection who had HBeAg had more severe immune suppression as compared to those with anti-HBe. This may have implication for initiating HAART in HBV endemic areas.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22095533</PMID><DateCreated><Year>2011</Year><Month>11</Month><Day>18</Day></DateCreated><DateCompleted><Year>2012</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2011</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J. Med. Virol.</ISOAbbreviation></Journal><ArticleTitle>Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.</ArticleTitle><Pagination><MedlinePgn>6-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.22262</ELocationID><Abstract><AbstractText>Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co-infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was screened for HBV and HCV serologic markers; HBsAg positive patients were tested for HBeAg, anti-HBe, and anti-HBc IgM. The viral load of HIV-1 in the plasma was determined in 81 patients. Eighteen of the 138 patients (13%) and 5 (3.6%) had HBsAg and anti-HCV, respectively. None of the patients had anti-HBc IgM, but 10 (55.6%) and 8 (44.4%) of the 18 patients who were HBsAg positive had HBeAg and anti-HBe, respectively. In patients with measurement of CD4(+) undertaken within 1 month (n = 83), CD4(+) count was significantly lower in patients with HBeAg (median [IQR], 81 [22-144]) as compared to those with anti-HBe (median [IQR], 210 [197-222]) (P = 0.002, CI: -96.46 to 51.21). However, those with HIV mono-infection had similar CD4(+) counts (median [IQR], 57 [14-159]) compared to those with HBeAg (P = 1.0, CI: -71.75 to 73.66). Similar results were obtained if CD4(+) count was measured within 2 months prior to initiation of HAART (n = 119). Generally, HBV and anti-HCV did not affect CD4(+) and viral loads of HIV-1 in plasma but patients with HIV and HBV co-infection who had HBeAg had more severe immune suppression as compared to those with anti-HBe. This may have implication for initiating HAART in HBV endemic areas.</AbstractText><CopyrightInformation>Copyright © 2011 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sagoe</LastName><ForeName>Kwamena William Coleman</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School, Accra, Ghana. kwcsagoe@chs.edu.gh</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agyei</LastName><ForeName>Afrakoma Adjoa</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Ziga</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Lartey</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Adiku</LastName><ForeName>Theophilus K</ForeName><Initials>TK</Initials></Author><Author ValidYN="Y"><LastName>Seshi</LastName><ForeName>Makafui</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Arens</LastName><ForeName>Max Q</ForeName><Initials>MQ</Initials></Author><Author ValidYN="Y"><LastName>Mingle</LastName><ForeName>Julius Abraham Addo</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006514">Hepatitis B Surface Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018937">Hepatitis C Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023241" MajorTopicYN="N">Antiretroviral Therapy, Highly Active</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006514" MajorTopicYN="N">Hepatitis B Surface Antigens</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018937" MajorTopicYN="N">Hepatitis C Antibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22095533</ArticleId><ArticleId IdType="doi">10.1002/jmv.22262</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000121 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000121 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:22095533
|texte= Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:22095533" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |